Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab in Episodic Migraine Prevention (ARISE)
NCT02483585Phase 3Completed
- Sponsor
- Amgen
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of erenumab in episodic migraine, sponsored by Amgen. Started Jul 2015; status: completed.
02
Drugs
erenumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT02483585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483585.